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A B S T R A C T
Catalytic bioscavengers are the second-generation bioscavengers. These biopharmaceuticals are intended to
degrade toxic organophosphorus agents on the skin for decontamination or in the bloodstream for pre-treatment
and post-exposure treatment of organophosphate poisoning. Because catalytic degradation has to be fast, their
catalytic eﬃciency has to be as high as possible (kcat/Km>106 M−1 min−1). Certain evolved mammalian
paraoxonases and bacterial phosphotriesterases already fulﬁll this requirement.
To be of interest, the catalytic activity of certain enzymes has to be increased by several orders of magnitude.
This can be reached by computer-redesign or directed evolution existing enzymes, and alternatively, combi-
national strategies.
The present paper focuses on the better understanding of catalytic mechanisms of cholinesterase inhibition,
aging and reactivation and how this knowledge serves the rational design of novel catalytic bioscavengers based
on cholinesterase structure.
1. Introduction
Limitations and multiple diﬃculties of current pretreatment and
post-exposure treatment of OP poisoning (Masson, 2016) have stimu-
lated scientists to research alternative approaches to classical pharma-
cological drugs. The idea of scavenging and neutralizing OP molecules
before they reach physiological targets progressively has emerged in
the 80 s. Some 30 years ago, the basic concepts of the bioscavenger
approach were already well established.
Three classes of bioscavengers can be deﬁned: a) stoichiometric
bioscavengers that react mole-to-mole with OPs in a suicide reaction, b)
catalytic bioscavengers that react with a turnover with substrate OPs, c)
pseudo-catalytic bioscavengers are stoichiometric bioscavengers as-
sisted of nucleophilic molecules (oximates) that displace the phosphyl
moiety, thus creating a pseudo-turnover. Several recent reviews were
devoted to the diﬀerent types of bioscavengers and their use with
conventional medical countermeasures (Satvik Iyengar et al., 2015;
Worek et al., 2016; Masson and Lushchekina, 2016; Masson and
Nachon, 2017; Goldsmith and Ashani, 2018). Requirements needed to
develop biopharmaceuticals of interest (bimolecular rate of reaction
with OPs, production under GMP conditions, delivery systems, capping
and encapsulation, pharmacokinetics, absence of side eﬀects, immuno-
compatibility and economic issues) have been discussed in above-cited
reviews. The present paper focuses on the basic knowledge needed to
design ChE-based catalytic bioscavengers capable of degrading OPs
with high eﬃciency.
2. Bioscavengers
Mandatory kinetic requirements determine the operational interest
of bioscavengers. Reaction between OP molecules and bioscavengers
has to be fast to prevent transfer of toxicant to targets. Moreover, be-
cause of narrow speciﬁcity and enantioselectivity, mixtures of biosca-
vengers must be administered to cover the whole spectrum of existing
OPs. In addition, bioscavengers must be stable, have a slow clearance in
the bloodstream, and they must not induce iatrogenic eﬀects.
Encapsulation into nanocontainers or chemical capping may prevent
immune response and fast elimination.
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